logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
H

Hans Prenen

university hospital antwerp
H指数:54
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors

Beamion PANTUMOR-1: Zongertinib二线临床试验的试验依据与设计，用于HER2过表达/扩增或HER2突变的实体瘤

Future Oncology
IF2.6
2026-03-040
PRE
Alison M. Schram; John J. Park; Antoine Italiano; Shigehisa Kitano; Ye Guo; Jin Li; Philippe L. Bedard; Cedric van Marcke; Ryo Ko; Lukas Lunger; Daniel M. Klotz; Jo Hussain; Daniela Maier; Damijan Erzen; David Planchard; Hans Prenen; Timothy D. Clay; Joon O. Park; Hyung-Don Kim; Alberto Hernando-Calvo; Yuta Maruki; Mariano Ponz-Sarvise; Ecaterina Dumbrava
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1

CD40激动剂米他扎利单抗联合mFOLFIRINOX治疗未治疗转移性胰腺癌：OPTIMIZE-1研究中与结局相关的生物标志物

Cell Reports Medicine
IF10.6
2025-10-070
OAAI
Jean-Luc Van Laethem; Karen Geboes; Ivan Borbath; Teresa Macarulla Mercade; Aurélien Lambert; Philippe Cassier; Hans Prenen; Emmanuel Mitry; Jean-Frédéric Blanc; Lorenzo Pilla; Jaime Feliu; Mercedes Rodriguez Garrote; Roberto Antonio Pazo-Cid; Inmaculada Gallego; Karin Enell Smith; Karin Nordbladh; David Gomez Jimenez; Peter Ellmark; Yago Pico de Coaña; Sumeet Vijay Ambarkhane; Gregory L. Beatty; Eileen M. O'Reilly
A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis

POLARIS研究的简明语言摘要：一项针对BRAF V600突变黑色素瘤脑转移患者，评估encorafenib联合binimetinib不同剂量的研究

FUTURE ONCOLOGY
IF2.6
2025-05-260
OA
Menzies, Alexander M.; Long, Georgina V.; Kohn, Amiee; Tawbi, Hussein; Webe, Jeffrey; Flaherty, Keith; McArthur, Grant A.; Ascierto, Paolo A.; Pfluger, Yanina; Lewis, Karl; Tsai, Katy K.; Hamid, Omid; Prenen, Hans; Fein, Luis; Wang, Erjian; Guenzel, Carolin; Zhang, Fan; Kleh, Joseph F.; di Pietro, Alessandra; Davies, Michael A.
Cracking the code of a correlate of protection against SARS-CoV-2 breakthrough infection in cancer patients
SCIENTIFIC REPORTS
IF3.9
2025-03-060
OAAI
Debie, Yana; Garcia-Fogeda, Irene; Willem, Lander; Roelant, Ella; Verbruggen, Lise; Vanhoutte, Greetje; Croes, Lieselot; Vulsteke, Christof; Demey, Wim; Lybaert, Willem; Hanssens, Marianne; Bols, Alain; Van Ongeval, Johan; De Becker, Ann; Jansens, Hilde; Goossens, Maria E.; Janssens, Annelies; Prenen, Hans; Anguille, Sebastien; Peeters, Marc; van Dam, Peter A.; Hens, Niel; Abrams, Steven; Vandamme, Timon
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration5

MTAP缺失的实体瘤患者中MTA合作PRMT5抑制剂AMG 193的首次人体研究: I期剂量探索的结果5

ANNALS OF ONCOLOGY
IF65.4
2024-12-014
PRE
Rodon, J.; Prenen, H.; Sacher, A.; Villalona-Calero, M.; Penel, N.; El Helali, A.; Rottey, S.; Yamamoto, N.; Ghiringhelli, F.; Goebeler, M. E.; Doi, T.; Postel-Vinay, S.; Lin, C. -c.; Liu, C.; Chuang, C. -h.; Keyvanjah, K.; Eggert, T.; Neil, B. h. o '
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma

simlukafusp alfa (FAP-IL2v) 联合阿特珠单抗治疗复发和/或转移性宫颈鳞状细胞癌患者的抗肿瘤活性和安全性的2期研究

EBIOMEDICINE
IF10.8
2024-11-011
PRE
Verlingue, Loic; Italiano, Antoine; Prenen, Hans; Alia, Eva Maria Guerra; Tosi, Diego; Perets, Ruth; Lugowska, Iwona; Moiseyenko, Vladimir; Gumus, Mahmut; Arslan, Cagatay; Lindsay, Colin R.; Deva, Sanjeev; Taus, Alvaro; Oaknin, Ana; Rottey, Sylvie; Cicin, Irfan; Goksu, Sema Sezgin; Smolin, Alexey; Rosello-Keranen, Susana; Habigt, Christin; Marbach, Daniel; Boetsch, Christophe; Dejardin, David; Sleiman, Nassim; Evers, Stefan; Richard, Muriel; Ardeshir, Caroline; Charo, Jehad; Kraxner, Anton; Teichgraber, Volker; Keshelava, Nino; Dziadziuszkoz, Rafal
A Phase 1a/1b Study of Fostroxacitabine Bralpamide (Fostrox) Monotherapy in Hepatocellular Carcinoma and Solid Tumor Liver Metastases
JOURNAL OF HEPATOCELLULAR CARCINOMA
IF3.4
2024-10-010
OAAI
Plummer, Ruth; Greystoke, Alastair; Naylor, Gregory; Sarker, Debashis; Anam, A. N. M. Kaiser; Prenen, Hans; Teuwen, Laure-Anne; Van Cutsem, Eric; Dekervel, Jeroen; Haugk, Beate; Ness, Thomas; Bhoi, Sujata; Jensen, Malene; Morris, Tom; Baumann, Pia; Sjogren, Niclas; Tunblad, Karin; Wallberg, Hans; Oberg, Fredrik; Evans, Thomas R. Jeffry
Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study
ESMO OPEN
IF8.3
2024-09-014
OAAI
Gallois, C.; Bergen, E. S.; Auclin, E.; Pernot, S.; Higue, J.; Trouilloud, I.; Touchefeu, Y.; Turpin, A.; Mazard, T.; Sartore-Bianchi, A.; Prenen, H.; Alberti, A.; Pilla, L.; Cuissy, S.; Wookey, V.; Perret, A.; Melchior, C.; Artru, P.; Dubreuil, O.; Drouillard, A.; Doat, S.; Lavole, J.; Basile, D.; Perkins, G.; Jary, M.; Stintzing, S.; Jos, J.; Tougeron, D.; Taieb, J.
Real-world usage and adverse events (AE) of immune checkpoint inhibitors (ICI): A large-scale, automated, GDPRcompliant analysis of hospital records

真实世界使用和免疫检查点抑制剂（ICI）的不良事件（AE）：一项大规模、自动化的GDPR合规性医院记录分析

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Verbiest, A. T. L.; Debruyne, P. R.; Bassez, I.; Delombaerde, D. L.; Tack, L.; Oeste, C. L.; Deckx, L.; Croes, L.; Hens, D. F. E.; Geldhof, V.; Prenen, H.; Vulsteke, C.
EphA2-targeting bicycle toxin conjugate (BTC) BT5528 in patients (pts) with advanced solid tumors: A phase I/II study

EphA2靶向环形分子毒素偶联物（BTC）BT5528在晚期实体瘤患者（pts）中的I/II期研究

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Fontana, E.; Wang, J. S.; Mckean, M.; Aljumaily, R.; Machiels, J-P.; Doger de Speville, B.; Vieito, M.; Carter, L.; Prenen, H.; Falchook, G. S.; Greystoke, A.; Feliu, W. I. Ortuzar; De, A.; Gu, X.; Li, M.; de Rienzo, A.; Bashir, B.
A randomized blinded phase II study of ompenaclid (RGX-202-01) vs placebo in combination with FOLFIRI plus bevacizumab (BEV) in patients (pts) with previously treated RAS mutated (RASmt) advanced/metastatic colorectal cancer (mCRC)

一项关于奥潘奈利（ompenaclid，RGX-202-01）与安慰剂在联合FOLFIRI方案加贝伐珠单抗（BEV）治疗既往接受过治疗的RAS突变（RASmt）晚期/转移性结直肠癌（mCRC）患者中的随机双盲II期研究

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Elez Fernandez, M. E.; Rosello Keranen, S.; Paez, D.; Jimenez Castro, J.; Rivera Herrero, F.; Ruiz-Casado, A.; Riesco Martinez, M. C.; Montagut Viladot, C.; Coupez, D.; Ducreux, M. P.; Loly, C.; Martin-Babau, J.; Prenen, H.; van den Eynde, M.; Borg, C.; Cuyle, P-J.; de Haar-Holleman, A.; Raimbourg, J.; Bechar, N.; Tabernero, J.
CD40 agonist mitazalimab combined with mFOLFIRINOX (mFFX) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Primary analysis of the OPTIMIZE-1 phase Ib/II study
ANNALS OF ONCOLOGY
IF65.4
2024-06-010
PRE
Macarulla Mercade, T.; Borbath, I.; Geboes, K.; Lambert, A.; Cassier, P.; Prenen, H.; Mitry, E.; Blanc, J. F.; Pilla, L.; Feliu, J.; Rodriguez, M.; Cid, R. A. Pazo; Gallego Jimenez, I.; Gomez Jimenez, D.; Smith, K. E.; Nordbladh, K.; Ellmark, P.; Pico de Coana, Y.; Ambarkhane, S. V.; van Laethem, J-L.
Interim efficacy analysis of REGINA, a phase II trial of neoadjuvant regorafenib (Rego), nivolumab (Nivo), and short-course radiotherapy (SCRT) in stage II-III rectal cancer (RC)
ANNALS OF ONCOLOGY
IF65.4
2024-06-010
PRE
Sclafani, F.; Bregni, G.; Assaf, I.; Puleo, F.; Vergauwe, P.; Prenen, H.; Diaz, M.; Gokburun, Y.; Sanchez, A. Veron; Anthoine, G.; Moretti, L.; Galdon, M. Gomez; Liberale, G.; Martinive, P.; Geboes, K.; Carrasco, J.; van den Eynde, M.; van Laethem, J-L.; Buyse, M. E.; Hendlisz, A.
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
CLINICAL CANCER RESEARCH
IF10.2
2024-05-061
PRE
Prenen, Hans; Deva, Sanjeev; Keam, Bhumsuk; Lindsay, Colin R.; Lugowska, Iwona; Yang, James C.; Longo, Federico; de Miguel, Maria; Ponz-Sarvise, Mariano; Ahn, Myung-Ju; Gumus, Mahmut; Champiat, Stephane; Italiano, Antoine; Salas, Sebastien; Perets, Ruth; Arslan, Cagatay; Cho, Byoung C.; Evers, Stefan; Boetsch, Christophe; Marbach, Daniel; Dejardin, David; Sleiman, Nassim; Ardeshir, Caroline; Richard, Muriel; Charo, Jehad; Kraxner, Anton; Keshelava, Nino; Teichgraeber, Volker; Moreno, Victor

研究方向

暂未获取到该数据
E
Eric Van Cutsem
H 指数:174论文数:1,832被引数:17.4万
M
Marc Peeters
H 指数:99论文数:1,379被引数:4.6万
M
Massimiliano Mazzone
H 指数:79论文数:436被引数:2.4万
C
Christof Vulsteke
H 指数:28论文数:191被引数:8,168
E
Evelien Smits
H 指数:57论文数:298被引数:1.0万
P
Peter A. van Dam
H 指数:59论文数:390被引数:1.0万
F
Filip Lardon
H 指数:53论文数:274被引数:8,541
C
Christophe Deben
H 指数:24论文数:88被引数:2,243
E
Eva Segelov
H 指数:35论文数:324被引数:4,660
J
Janssens, Annelies
H 指数:0论文数:1被引数:66